About

About
The DS management team has both a strong background in developing drugs for the market and experience in building life science companies.

Pipeline

Pipeline
DS Biopharma have three novel assets in various stages of clinical development and intend to add more bioactive lipids to the current portfolio in the coming years.

Investors

Investors
To date, DS Biopharma have been funded privately.

Latest Press Releases

October 5, 2021

DS BIOPHARMA AND NDSU ENTER LICENSE AGREEMENT TO DEVELOP DALEUTON AS PART OF A NOVEL CANCER TREATMENT TARGETING THE TUMOR MICROENVIRONMENT

Dublin, Ireland and North Dakota, USA, October 5th 2021 DS Biopharma Limited, a developer of bioactive lipid-based pharmaceuticals and the NDSU Research Foundation today announced they […]
March 18, 2021

DS Biopharma and Nuvothera Enter Option and License Agreement for EPADILIN®

• Nuvothera acquires option to licence rights to develop and commercialise DS Biopharma’s EPADILIN® in the US • DS Biopharma becomes an investor in Nuvothera and […]

Publications and Media Coverage

January 19, 2021

DS BIOPHARMA ABSTRACTS ACCEPTED AT THE ATOPIC DERMATITIS CENTRE OF REFERENCE AND EXCELLENCE (ADCARE) 2021 CONFERENCE

DS Biopharma (DS) has successfully submitted two abstracts to the Atopic Dermatitis Centre of Reference and Excellence (ADCARE) 2021 conference. A link to the abstract “Steroid-sparing […]
November 19, 2019

Pipeline full with agents in various phases of development | Dermatology Times

The following article appeared in Dermatology Times on 19th November 2019: https://www.dermatologytimes.com/atopic-dermatitis/pipeline-full-agents-various-phases-development As dermatologists gain experience with newer atopic dermatitis medications, they’re getting glimpses of data […]

Join our mailing list

Connect with us